Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Protalix ( (PLX) ) has issued an announcement.
On October 17, 2025, Protalix BioTherapeutics and its partner Chiesi Global Rare Diseases announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on the proposed dosing regimen for Elfabrio®. This decision may impact the company’s market strategy and regulatory approach for Elfabrio® in Europe, potentially affecting stakeholders and future commercial plans.
The most recent analyst rating on (PLX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Protalix stock, see the PLX Stock Forecast page.
Spark’s Take on PLX Stock
According to Spark, TipRanks’ AI Analyst, PLX is a Neutral.
Protalix’s overall stock score reflects strong earnings growth and promising product developments, offset by high leverage and inconsistent revenue growth. The recent CFO appointment and technical indicators suggest potential for future improvement.
To see Spark’s full report on PLX stock, click here.
More about Protalix
Protalix BioTherapeutics, Inc. is a pharmaceutical company specializing in the development of recombinant proteins for the treatment of rare diseases. The company is known for its proprietary ProCellEx® platform, which focuses on plant cell protein expression and enzyme replacement therapies. Protalix has commercialized products such as Elfabrio® and Elelyso, with global partnerships including Chiesi Global Rare Diseases and Pfizer Inc.
Average Trading Volume: 702,725
Technical Sentiment Signal: Buy
Current Market Cap: $191.4M
See more insights into PLX stock on TipRanks’ Stock Analysis page.